CI Stock Recent News
CI LATEST HEADLINES
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BLOOMFIELD, Conn. , Oct. 3, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2024 financial results on Thursday, October 31, 2024, and will host a conference call the same day.
CVS Health and Cigna on Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above, saying some members would pay $0 premium monthly for prescription drugs.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value.
CNBC's Eamon Javers joins 'The Exchange' to report the latest on the FTC's lawsuit against drug middlemen for allegedly inflating insulin prices.
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.
The US Federal Trade Commission is accusing units of CVS, Cigna, and UnitedHealth of engaging in illegal rebate programs that drove up the price of insulin. Federal Trade Commission Office of Public Affairs Director Douglas Farrar discusses the lawsuit against the pharmacy benefits managers.
The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.
The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while "artificially" inflating costs for patients. The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts, and their affiliated group purchasing organizations.